# DAFTAR PUSTAKA


Abbasifard, M., & Khorramdelazad, H. (2020). The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. *Life sciences*, *257*, 118097. https://doi.org/10.1016/j.lfs.2020.118097

Abou-Ismail, M. Y., Diamond, A., Kapoor, S., Arafah, Y., & Nayak, L. (2020). The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. *Thrombosis research*, *194*, 101–115. https://doi.org/10.1016/j.thromres.2020.06.029

Al-Salameh, A., Lanoix, J. P., Bennis, Y., Andrejak, C., Brochot, E., Deschasse, G., Dupont, H., Goeb, V., Jaureguy, M., Lion, S., Maizel, J., Moyet, J., Vaysse, B., Desailloud, R., Ganry, O., Schmit, J. L., & Lalau, J. D. (2021). Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes. *Diabetes/metabolism research and reviews*, *37*(3), e3388. https://doi.org/10.1002/dmrr.3388

Alfano, G., Ferrari, A., Fontana, F., Perrone, R., Mori, G., Ascione, E., Magistroni, R., Venturi, G., Pederzoli, S., Margiotta, G., Romeo, M., Piccinini, F., Franceschi, G., Volpi, S., Faltoni, M., Ciusa, G., Bacca, E., Tutone, M., Raimondi, A., Menozzi, M., … Modena Covid-19 Working Group (MoCo19) (2021). Hypokalemia in Patients with COVID-19. *Clinical and experimental nephrology*, *25*(4), 401–409. https://doi.org/10.1007/s10157-020-01996-4

Alharthy, A., Aletreby, W., Faqihi, F., Balhamar, A., Alaklobi, F., Alanezi, K., Jaganathan, P., Tamim, H., Alqahtani, S. A., Karakitsos, D., & Memish, Z. A. (2021). Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study. *Journal of epidemiology and global health*, *11*(1), 98–104. https://doi.org/10.2991/jegh.k.200928.001

Aleissa, M. M., Silverman, E. A., Paredes Acosta, L. M., Nutt, C. T., Richterman, A., & Marty, F. M. (2020). New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19. *Antimicrobial agents and chemotherapy*, *65*(1), e01814-20. https://doi.org/10.1128/AAC.01814-20

Ali N. (2020). Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. *Journal of medical virology*, *92*(11), 2409–2411. https://doi.org/10.1002/jmv.26097

Antinori, S., Cossu, M. V., Ridolfo, A. L., Rech, R., Bonazzetti, C., Pagani, G., Gubertini, G., Coen, M., Magni, C., Castelli, A., Borghi, B., Colombo, R., Giorgi, R., Angeli, E., Mileto, D., Milazzo, L., Vimercati, S., Pellicciotta, M., Corbellino, M., Torre, A., … Galli, M. (2020). Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. *Pharmacological research*, *158*, 104899. https://doi.org/10.1016/j.phrs.2020.104899

Armstrong, R. A., Kane, A. D., & Cook, T. M. (2020). Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies. *Anaesthesia*, *75*(10), 1340–1349. https://doi.org/10.1111/anae.15201

Assiri, A., Iqbal, M. J., Mohammed, A., Alsaleh, A., Assiri, A., Noor, A., Nour, R., & Khobrani, M. (2021). COVID-19 related treatment and outcomes among COVID-19 ICU patients: A retrospective cohort study. *Journal of infection and public health*, *14*(9), 1274–1278. https://doi.org/10.1016/j.jiph.2021.08.030

Bartsch, S. M., O'Shea, K. J., Ferguson, M. C., Bottazzi, M. E., Wedlock, P. T., Strych, U., McKinnell, J. A., Siegmund, S. S., Cox, S. N., Hotez, P. J., & Lee, B. Y. (2020). Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. *American journal of preventive medicine*, *59*(4), 493–503. https://doi.org/10.1016/j.amepre.2020.06.011

Baumeister, D., Akhtar, R., Ciufolini, S., Pariante, C. M., & Mondelli, V. (2016). Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α. *Molecular psychiatry*, *21*(5), 642–649. https://doi.org/10.1038/mp.2015.67

Bchetnia, M., Girard, C., Duchaine, C., & Laprise, C. (2020). The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. *Journal of infection and public health*, *13*(11), 1601–1610. https://doi.org/10.1016/j.jiph.2020.07.011

Bergamaschi, G., Borrelli de Andreis, F., Aronico, N., Lenti, M. V., Barteselli, C., Merli, S., Pellegrino, I., Coppola, L., Cremonte, E. M., Croce, G., Mordà, F., Lapia, F., Ferrari, S., Ballesio, A., Parodi, A., Calabretta, F., Ferrari, M. G., Fumoso, F., Gentile, A., Melazzini, F., … Internal Medicine Covid-19 Collaborators (2021). Anemia in patients with Covid-19: pathogenesis and clinical significance. *Clinical and experimental medicine*, *21*(2), 239–246. https://doi.org/10.1007/s10238-020-00679-4

Bertolini, A., van de Peppel, I. P., Bodewes, F., Moshage, H., Fantin, A., Farinati, F., Fiorotto, R., Jonker, J. W., Strazzabosco, M., Verkade, H. J., & Peserico, G. (2020). Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. *Hepatology (Baltimore, Md.)*, *72*(5), 1864–1872. https://doi.org/10.1002/hep.31480

Cecconi, M., Piovani, D., Brunetta, E., Aghemo, A., Greco, M., Ciccarelli, M., Angelini, C., Voza, A., Omodei, P., Vespa, E., Pugliese, N., Parigi, T. L., Folci, M., Danese, S., & Bonovas, S. (2020). Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy. *Journal of clinical medicine*, *9*(5), 1548. https://doi.org/10.3390/jcm9051548

Cohen J. (2020). Wuhan seafood market may not be source of novel virus spreading globally. Science. https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novelvirus-spreading-globally.

COVID-19 Treatment Guidelines Panel. (2020). *Coronavirus Disease 2019 (COVID-19) Treatment Guidelines*. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed [2021 Jan].

Covino, M., Sandroni, C., Santoro, M., Sabia, L., Simeoni, B., Bocci, M. G., Ojetti, V., Candelli, M., Antonelli, M., Gasbarrini, A., & Franceschi, F. (2020). Predicting intensive care unit admission and death for COVID-19 patients in the emergency department using early warning scores. *Resuscitation*, *156*, 84–91. https://doi.org/10.1016/j.resuscitation.2020.08.124

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet (London, England)*, *395*(10223), 507–513. https://doi.org/10.1016/S0140-6736(20)30211-7

Dahdouh, E., Lázaro-Perona, F., Romero-Gómez, M. P., Mingorance, J., & García-Rodriguez, J. (2021). $C_t$ values from SARS-CoV-2 diagnostic PCR assays should not be used as direct estimates of viral load. *The Journal of infection*, *82*(3), 414–451. https://doi.org/10.1016/j.jinf.2020.10.017

Dalia, T., Lahan, S., Ranka, S., Acharya, P., Gautam, A., Goyal, A., Mastoris, I., Sauer, A., & Shah, Z. (2021). Impact of congestive heart failure and role of cardiac biomarkers in COVID-19 patients: A systematic review and meta-analysis. *Indian heart journal*, *73*(1), 91–98. https://doi.org/10.1016/j.ihj.2020.12.002

Del Sole, F., Farcomeni, A., Loffredo, L., Carnevale, R., Menichelli, D., Vicario, T., Pignatelli, P., & Pastori, D. (2020). Features of severe COVID-19: A systematic review and meta-analysis. *European journal of clinical investigation*, *50*(10), e13378. https://doi.org/10.1111/eci.13378

Dhama, K., Khan, S., Tiwari, R., Sircar, S., Bhat, S., Malik, Y. S., Singh, K. P., Chaicumpa, W., Bonilla-Aldana, D. K., & Rodriguez-Morales, A. J. (2020).

Coronavirus Disease 2019-COVID-19. *Clinical microbiology reviews*, *33*(4), e00028-20. https://doi.org/10.1128/CMR.00028-20

Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., & Smith, L. (2020). Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. *International journal of environmental research and public health*, *17*(8), 2690. https://doi.org/10.3390/ijerph17082690

Du, W., Han, S., Li, Q., & Zhang, Z. (2020). Epidemic update of COVID-19 in Hubei Province compared with other regions in China. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*, *95*, 321–325. https://doi.org/10.1016/j.ijid.2020.04.031

Eccles R. (2005). Understanding the symptoms of the common cold and influenza. *The Lancet. Infectious diseases*, *5*(11), 718–725. https://doi.org/10.1016/S1473-3099(05)70270-X

Ellul, M. A., Benjamin, L., Singh, B., Lant, S., Michael, B. D., Easton, A., Kneen, R., Defres, S., Sejvar, J., & Solomon, T. (2020). Neurological associations of COVID-19. *The Lancet. Neurology*, *19*(9), 767–783. https://doi.org/10.1016/S1474-4422(20)30221-0

Esakandari, H., Nabi-Afjadi, M., Fakkari-Afjadi, J., Farahmandian, N., Miresmaeili, S. M., & Bahreini, E. (2020). A comprehensive review of COVID-19 characteristics. *Biological procedures online*, *22*, 19. https://doi.org/10.1186/s12575-020-00128-2

Fathi, N., & Rezaei, N. (2020). Lymphopenia in COVID-19: Therapeutic opportunities. *Cell biology international*, *44*(9), 1792–1797. https://doi.org/10.1002/cbin.11403

Flythe, J. E., Assimon, M. M., Tugman, M. J., Chang, E. H., Gupta, S., Shah, J., Sosa, M. A., Renaghan, A. D., Melamed, M. L., Wilson, F. P., Neyra, J. A., Rashidi, A., Boyle, S. M., Anand, S., Christov, M., Thomas, L. F., Edmonston, D., Leaf, D. E., & STOP-COVID Investigators (2021).

Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States. *American journal of kidney diseases : the official journal of the National Kidney Foundation*, *77*(2), 190–203.e1. https://doi.org/10.1053/j.ajkd.2020.09.003

Gagliardi, I., Patella, G., Michael, A., Serra, R., Provenzano, M., & Andreucci, M. (2020). COVID-19 and the Kidney: From Epidemiology to Clinical Practice. *Journal of clinical medicine*, *9*(8), 2506. https://doi.org/10.3390/jcm9082506

Gallo Marin, B., Aghagoli, G., Lavine, K., Yang, L., Siff, E. J., Chiang, S. S., Salazar-Mather, T. P., Dumenco, L., Savaria, M. C., Aung, S. N., Flanigan, T., & Michelow, I. C. (2021). Predictors of COVID-19 severity: A literature review. *Reviews in medical virology*, *31*(1), 1–10. https://doi.org/10.1002/rmv.2146

Gautret, P., Million, M., Jarrot, P. A., Camoin-Jau, L., Colson, P., Fenollar, F., Leone, M., La Scola, B., Devaux, C., Gaubert, J. Y., Mege, J. L., Vitte, J., Melenotte, C., Rolain, J. M., Parola, P., Lagier, J. C., Brouqui, P., & Raoult, D. (2020). Natural history of COVID-19 and therapeutic options. *Expert review of clinical immunology*, *16*(12), 1159–1184. https://doi.org/10.1080/1744666X.2021.1847640

Gavriatopoulou, M., Ntanasis-Stathopoulos, I., Korompoki, E., Fotiou, D., Migkou, M., Tzanninis, I. G., Psaltopoulou, T., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2021). Emerging treatment strategies for COVID-19 infection. *Clinical and experimental medicine*, *21*(2), 167–179. https://doi.org/10.1007/s10238-020-00671-y

Ge, H., Wang, X., Yuan, X., Xiao, G., Wang, C., Deng, T., . . . Xiao, X. (2020). The epidemiology and clinical information about COVID-19. *European Journal of Clinical Microbiology & Infectious Diseases, 39*(6), 1011-1019. doi:10.1007/s10096-020-03874-

Ghasemnejad-Berenji, M., & Pashapour, S. (2021). Favipiravir and COVID-19: A Simplified Summary. *Drug research*, *71*(3), 166–170. https://doi.org/10.1055/a-1296-7935

Ghayda, R. A., Lee, J., Lee, J. Y., Kim, D. K., Lee, K. H., Hong, S. H., Han, Y. J., Kim, J. S., Yang, J. W., Kronbichler, A., Smith, L., Koyanagi, A., Jacob, L., & Shin, J. I. (2020). Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis. *International journal of environmental research and public health*, *17*(14), 5026. https://doi.org/10.3390/ijerph17145026

Giagulli, V. A., Guastamacchia, E., Magrone, T., Jirillo, E., Lisco, G., De Pergola, G., & Triggiani, V. (2021). Worse progression of COVID-19 in men: Is testosterone a key factor?. *Andrology*, *9*(1), 53–64. https://doi.org/10.1111/andr.12836

Gibson, P. G., Qin, L., & Puah, S. H. (2020). COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. *The Medical journal of Australia*, *213*(2), 54–56.e1. https://doi.org/10.5694/mja2.50674

Grant, M. C., Geoghegan, L., Arbyn, M., Mohammed, Z., McGuinness, L., Clarke, E. L., & Wade, R. G. (2020). The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. *PloS one*, *15*(6), e0234765. https://doi.org/10.1371/journal.pone.0234765

Gavriatopoulou, M., Ntanasis-Stathopoulos, I., Korompoki, E., Fotiou, D., Migkou, M., Tzanninis, I. G., Psaltopoulou, T., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2021). Emerging treatment strategies for COVID-19 infection. *Clinical and experimental medicine*, *21*(2), 167–179. https://doi.org/10.1007/s10238-020-00671-y

Guo, Y. R., Cao, Q. D., Hong, Z. S., Tan, Y. Y., Chen, S. D., Jin, H. J., Tan, K. S., Wang, D. Y., & Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on

the status. *Military Medical Research*, *7*(1), 11. https://doi.org/10.1186/s40779-020-00240-0

Haase, N., Plovsing, R., Christensen, S., Poulsen, L. M., Brøchner, A. C., Rasmussen, B. S., Helleberg, M., Jensen, J., Andersen, L., Siegel, H., Ibsen, M., Jørgensen, V., Winding, R., Iversen, S., Pedersen, H. P., Madsen, J., Sølling, C., Garcia, R. S., Michelsen, J., Mohr, T., … Perner, A. (2021). Characteristics, interventions, and longer term outcomes of COVID-19 ICU patients in Denmark-A nationwide, observational study. *Acta anaesthesiologica Scandinavica*, *65*(1), 68–75. https://doi.org/10.1111/aas.13701

Hafeez, A., Ahmad, S., Siddqui, S. A., Ahmad, M., & Mishra, S. (2020). A review of COVID-19 (CORONAVIRUS Disease-2019) Diagnosis, treatments and Prevention. *Eurasian Journal of Medicine and Oncology*, *4*(2), 116-125. doi:10.14744/ejmo.2020.90853

Hirose, R., Ikegaya, H., Naito, Y., Watanabe, N., Yoshida, T., Bandou, R., Daidoji, T., Itoh, Y., & Nakaya, T. (2021). Survival of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Virus on Human Skin: Importance of Hand Hygiene in Coronavirus Disease 2019 (COVID-19). *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, *73*(11), e4329–e4335. https://doi.org/10.1093/cid/ciaa1517

Hu, R., Han, C., Pei, S., Yin, M., & Chen, X. (2020). Procalcitonin levels in COVID-19 patients. *International journal of antimicrobial agents*, *56*(2), 106051. https://doi.org/10.1016/j.ijantimicag.2020.106051

Huang, I., Lim, M. A., & Pranata, R. (2020). Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. *Diabetes & metabolic syndrome*, *14*(4), 395–403. https://doi.org/10.1016/j.dsx.2020.04.018

Huang, J., Cheng, A., Kumar, R., Fang, Y., Chen, G., Zhu, Y., & Lin, S. (2020). Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. *Journal of medical virology*, *92*(10), 2152–2158. https://doi.org/10.1002/jmv.26003

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*, *395*(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

Huppert, L. A., Matthay, M. A., & Ware, L. B. (2019). Pathogenesis of Acute Respiratory Distress Syndrome. *Seminars in respiratory and critical care medicine*, *40*(1), 31–39. https://doi.org/10.1055/s-0039-1683996

Immovilli, P., Morelli, N., Antonucci, E., Radaelli, G., Barbera, M., & Guidetti, D. (2020). COVID-19 mortality and ICU admission: the Italian experience. *Critical care (London, England)*, *24*(1), 228. https://doi.org/10.1186/s13054-020-02957-9

Ito, J., Seo, R., Kawakami, D., Matsuoka, Y., Ouchi, K., Nonami, S., Miyoshi, Y., Tatebe, M., Tsuchida, T., Asaka, Y., Yanai, M., Ueta, H., Shimozono, T., Mima, H., Doi, A., Tomii, K., & Ariyoshi, K. (2021). Clinical characteristics and outcomes of critically ill patients with COVID-19 in Kobe, Japan: a single-center, retrospective, observational study. *Journal of anesthesia*, *35*(2), 213–221. https://doi.org/10.1007/s00540-021-02897-w

Izcovich, A., Ragusa, M. A., Tortosa, F., Lavena Marzio, M. A., Agnoletti, C., Bengolea, A., Ceirano, A., Espinosa, F., Saavedra, E., Sanguine, V., Tassara, A., Cid, C., Catalano, H. N., Agarwal, A., Foroutan, F., & Rada, G. (2020). Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. *PloS one*, *15*(11), e0241955. https://doi.org/10.1371/journal.pone.0241955

Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., & Duan, G. (2020). Virology, Epidemiology, Pathogenesis, and Control of COVID-19. *Viruses*, *12*(4), 372. https://doi.org/10.3390/v12040372

Jothimani, D., Venugopal, R., Abedin, M. F., Kaliamoorthy, I., & Rela, M. (2020). COVID-19 and the liver. *Journal of hepatology*, *73*(5), 1231–1240. https://doi.org/10.1016/j.jhep.2020.06.006

Kant, S., Menez, S. P., Hanouneh, M., Fine, D. M., Crews, D. C., Brennan, D. C., Sperati, C. J., & Jaar, B. G. (2020). The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation. *BMC nephrology*, *21*(1), 449. https://doi.org/10.1186/s12882-020-02112-0

Karahasan Yagci, A., Sarinoglu, R. C., Bilgin, H., Yanılmaz, Ö., Sayın, E., Deniz, G., Guncu, M. M., Doyuk, Z., Barıs, C., Kuzan, B. N., Aslan, B., Korten, V., & Cimsit, C. (2020). Relationship of the cycle threshold values of SARS-CoV-2 polymerase chain reaction and total severity score of computerized tomography in patients with COVID 19. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*, *101*, 160–166. https://doi.org/10.1016/j.ijid.2020.09.1449

Karampela, I., & Dalamaga, M. (2020). Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?. *Archives of medical research*, *51*(7), 741–742. https://doi.org/10.1016/j.arcmed.2020.06.004

Kemenkes. (2020). *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.01/MENKES/413/2020 039 tentang Pedoman Pencegahan dan Pengendalian Coronavirus Disease 2019 (Covid-19)*

Kim, L., Garg, S., O'Halloran, A., Whitaker, M., Pham, H., Anderson, E. J., Armistead, I., Bennett, N. M., Billing, L., Como-Sabetti, K., Hill, M., Kim, S., Monroe, M. L., Muse, A., Reingold, A. L., Schaffner, W., Sutton, M., Talbot, H. K., Torres, S. M., Yousey-Hindes, K., … Langley, G. E. (2021). Risk Factors for Intensive Care Unit Admission and In-hospital Mortality

Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, *72*(9), e206–e214. https://doi.org/10.1093/cid/ciaa1012

Kolhe, N. V., Fluck, R. J., Selby, N. M., & Taal, M. W. (2020). Acute kidney injury associated with COVID-19: A retrospective cohort study. *PLoS medicine*, *17*(10), e1003406. https://doi.org/10.1371/journal.pmed.1003406

Kumar, A., Arora, A., Sharma, P., Anikhindi, S. A., Bansal, N., Singla, V., Khare, S., & Srivastava, A. (2020). Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes & metabolic syndrome*, *14*(4), 535–545. https://doi.org/10.1016/j.dsx.2020.04.044

Kunutsor, S. K., & Laukkanen, J. A. (2020). Renal complications in COVID-19: a systematic review and meta-analysis. *Annals of medicine*, *52*(7), 345–353. https://doi.org/10.1080/07853890.2020.1790643

Li, B., Yang, J., Zhao, F., Zhi, L., Wang, X., Liu, L., Bi, Z., & Zhao, Y. (2020). Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clinical research in cardiology : official journal of the German Cardiac Society*, *109*(5), 531–538. https://doi.org/10.1007/s00392-020-01626-9

Li, L. Q., Huang, T., Wang, Y. Q., Wang, Z. P., Liang, Y., Huang, T. B., Zhang, H. Y., Sun, W., & Wang, Y. (2020). COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *Journal of medical virology*, *92*(6), 577–583. https://doi.org/10.1002/jmv.25757

Li, K., Wu, J., Wu, F., Guo, D., Chen, L., Fang, Z., & Li, C. (2020). The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia. *Investigative radiology*, *55*(6), 327–331. https://doi.org/10.1097/RLI.0000000000000672

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K., Lau, E., Wong, J. Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu,

T., Zhao, J., Liu, M., Tu, W., … Feng, Z. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *The New England journal of medicine*, *382*(13), 1199–1207. https://doi.org/10.1056/NEJMoa2001316

Lima-Martínez, M. M., Carrera Boada, C., Madera-Silva, M. D., Marín, W., & Contreras, M. (2021). COVID-19 and diabetes: A bidirectional relationship. COVID-19 y diabetes mellitus: una relación bidireccional. *Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis*, *33*(3), 151–157. https://doi.org/10.1016/j.arteri.2020.10.001

Lippi, G., Plebani, M., & Henry, B. M. (2020). Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clinica chimica acta; international journal of clinical chemistry*, *506*, 145–148. https://doi.org/10.1016/j.cca.2020.03.022

Long, C., Xu, H., Shen, Q., Zhang, X., Fan, B., Wang, C., Zeng, B., Li, Z., Li, X., & Li, H. (2020). Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?. *European journal of radiology*, *126*, 108961. https://doi.org/10.1016/j.ejrad.2020.108961

López-Collazo, E., Avendaño-Ortiz, J., Martín-Quirós, A., & Aguirre, L. A. (2020). Immune Response and COVID-19: A mirror image of Sepsis. *International journal of biological sciences*, *16*(14), 2479–2489. https://doi.org/10.7150/ijbs.48400

Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., Chen, J., … Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet (London, England)*, *395*(10224), 565–574. https://doi.org/10.1016/S0140-6736(20)30251-8

Luo, X., Zhou, W., Yan, X., Guo, T., Wang, B., Xia, H., Ye, L., Xiong, J., Jiang, Z., Liu, Y., Zhang, B., & Yang, W. (2020). Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, *71*(16), 2174–2179. https://doi.org/10.1093/cid/ciaa641

Marchioni, E., & Minoli, L. (2010). Headache attributed to infections nosography and differential diagnosis. *Handbook of clinical neurology*, *97*, 601–626. https://doi.org/10.1016/S0072-9752(10)97052-8

Martinot, M., Eyriey, M., Gravier, S., Bonijoly, T., Kayser, D., Ion, C., Mohseni-Zadeh, M., Camara, S., Dubois, J., Haerrel, E., Drouaine, J., Kaiser, J., Ongagna, J. C., Schieber-Pachart, A., Kempf, C., & Centre Alsace COVID-19 Study Group (2021). Predictors of mortality, ICU hospitalization, and extrapulmonary complications in COVID-19 patients. *Infectious diseases now*, *51*(6), 518–525. https://doi.org/10.1016/j.idnow.2021.07.002

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J., & HLH Across Speciality Collaboration, UK (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet (London, England)*, *395*(10229), 1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0

Mjaess, G., Karam, A., Aoun, F., Albisinni, S., & Roumeguère, T. (2020). COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. *Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie*, *30*(10), 484–487. https://doi.org/10.1016/j.purol.2020.05.007

Mo, P., Xing, Y., Xiao, Y., Deng, L., Zhao, Q., Wang, H., Xiong, Y., Cheng, Z., Gao, S., Liang, K., Luo, M., Chen, T., Song, S., Ma, Z., Chen, X., Zheng, R., Cao, Q., Wang, F., & Zhang, Y. (2020). Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of*

*America*, ciaa270. Advance online publication. https://doi.org/10.1093/cid/ciaa270

Mohamed, M. S., Moulin, T. C., & Schiöth, H. B. (2021). Sex differences in COVID-19: the role of androgens in disease severity and progression. *Endocrine*, *71*(1), 3–8. https://doi.org/10.1007/s12020-020-02536-6

Mustafa Hellou, M., Górska, A., Mazzaferri, F., Cremonini, E., Gentilotti, E., De Nardo, P., Poran, I., Leeflang, M. M., Tacconelli, E., & Paul, M. (2021). Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*, *27*(3), 341–351. https://doi.org/10.1016/j.cmi.2020.11.002

Ñamendys-Silva, S. A., Alvarado-Ávila, P. E., Domínguez-Cherit, G., Rivero-Sigarroa, E., Sánchez-Hurtado, L. A., Gutiérrez-Villaseñor, A., Romero-González, J. P., Rodríguez-Bautista, H., García-Briones, A., Garnica-Camacho, C. E., Cruz-Ruiz, N. G., González-Herrera, M. O., García-Guillén, F. J., Guerrero-Gutiérrez, M. A., Salmerón-González, J. D., Romero-Gutiérrez, L., Canto-Castro, J. L., Cervantes, V. H., & Mexico COVID-19 Critical Care Collaborative Group (2021). Outcomes of patients with COVID-19 in the intensive care unit in Mexico: A multicenter observational study. *Heart & lung : the journal of critical care*, *50*(1), 28–32. https://doi.org/10.1016/j.hrtlng.2020.10.013

Nannoni, S., de Groot, R., Bell, S., & Markus, H. S. (2021). Stroke in COVID-19: A systematic review and meta-analysis. *International journal of stroke : official journal of the International Stroke Society*, *16*(2), 137–149. https://doi.org/10.1177/1747493020972922

Navas-Blanco, J. R., & Dudaryk, R. (2020). Management of Respiratory Distress Syndrome due to COVID-19 infection. *BMC anesthesiology*, *20*(1), 177. https://doi.org/10.1186/s12871-020-01095-7

Nori, P., Cowman, K., Chen, V., Bartash, R., Szymczak, W., Madaline, T., Punjabi Katiyar, C., Jain, R., Aldrich, M., Weston, G., Gialanella, P., Corpuz, M., Gendlina, I., & Guo, Y. (2021). Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. *Infection control and hospital epidemiology*, *42*(1), 84–88. https://doi.org/10.1017/ice.2020.368

O'Driscoll, M., Ribeiro Dos Santos, G., Wang, L., Cummings, D., Azman, A. S., Paireau, J., Fontanet, A., Cauchemez, S., & Salje, H. (2021). Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*, *590*(7844), 140–145. https://doi.org/10.1038/s41586-020-2918-0

Parasher A. (2021). COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgraduate medical journal*, *97*(1147), 312–320. https://doi.org/10.1136/postgradmedj-2020-138577

Pascarella, G., Strumia, A., Piliego, C., Bruno, F., Del Buono, R., Costa, F., Scarlata, S., & Agrò, F. E. (2020). COVID-19 diagnosis and management: a comprehensive review. *Journal of internal medicine*, *288*(2), 192–206. https://doi.org/10.1111/joim.13091

Pedersen, S. F., & Ho, Y. C. (2020). SARS-CoV-2: a storm is raging. *The Journal of clinical investigation*, *130*(5), 2202–2205. https://doi.org/10.1172/JCI137647

Pedoman Tatalaksana Covid-19. (2021). Edisi 3.

Poggiali, E., Zaino, D., Immovilli, P., Rovero, L., Losi, G., Dacrema, A., Nuccetelli, M., Vadacca, G. B., Guidetti, D., Vercelli, A., Magnacavallo, A., Bernardini, S., & Terracciano, C. (2020). Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. *Clinica chimica acta; international journal of clinical chemistry*, *509*, 135–138. https://doi.org/10.1016/j.cca.2020.06.012

Pollard, C. A., Morran, M. P., & Nestor-Kalinoski, A. L. (2020). The COVID-19 pandemic: a global health crisis. *Physiological genomics*, *52*(11), 549–557. https://doi.org/10.1152/physiolgenomics.00089.2020

Potere, N., Batticciotto, A., Vecchié, A., Porreca, E., Cappelli, A., Abbate, A., Dentali, F., & Bonaventura, A. (2021). The role of IL-6 and IL-6 blockade in COVID-19. *Expert review of clinical immunology*, 1–17. Advance online publication. https://doi.org/10.1080/1744666X.2021.1919086

Pradhan, A. D., Manson, J. E., Rifai, N., Buring, J. E., & Ridker, P. M. (2001). C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA*, *286*(3), 327–334. https://doi.org/10.1001/jama.286.3.327

Ranzani, O. T., Bastos, L., Gelli, J., Marchesi, J. F., Baião, F., Hamacher, S., & Bozza, F. A. (2021). Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. *The Lancet. Respiratory medicine*, *9*(4), 407–418. https://doi.org/10.1016/S2213-2600(20)30560-9

Rey, J. R., Caro-Codón, J., Rosillo, S. O., Iniesta, Á. M., Castrejón-Castrejón, S., Marco-Clement, I., Martín-Polo, L., Merino-Argos, C., Rodríguez-Sotelo, L., García-Veas, J. M., Martínez-Marín, L. A., Martínez-Cossiani, M., Buño, A., Gonzalez-Valle, L., Herrero, A., López-Sendón, J. L., Merino, J. L., & CARD-COVID Investigators (2020). Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. *European journal of heart failure*, *22*(12), 2205–2215. https://doi.org/10.1002/ejhf.1990

Rizzo, A. N., Aman, J., van Nieuw Amerongen, G. P., & Dudek, S. M. (2015). Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome. *Arteriosclerosis, thrombosis, and vascular biology*, *35*(5), 1071–1079. https://doi.org/10.1161/ATVBAHA.115.305085

Rod, J. E., Oviedo-Trespalacios, O., & Cortes-Ramirez, J. (2020). A brief-review of the risk factors for covid-19 severity. *Revista de saude publica*, *54*, 60. https://doi.org/10.11606/s1518-8787.2020054002481

Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez-Ocampo, E., Villamizar-Peña, R., Holguin-Rivera, Y., Escalera-Antezana, J. P., Alvarado-Arnez, L. E., Bonilla-Aldana, D. K., Franco-Paredes, C., Henao-Martinez, A. F., Paniz-Mondolfi, A., Lagos-Grisales, G. J., Ramírez-Vallejo, E., Suárez, J. A., Zambrano, L. I., Villamil-Gómez, W. E., Balbin-Ramon, G. J., Rabaan, A. A., Harapan, H., Dhama, K., … Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Electronic address: https://www.lancovid.org (2020). Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel medicine and infectious disease*, *34*, 101623. https://doi.org/10.1016/j.tmaid.2020.101623

Runacres, A., Mackintosh, K. A., Knight, R. L., Sheeran, L., Thatcher, R., Shelley, J., & McNarry, M. A. (2021). Impact of the COVID-19 Pandemic on Sedentary Time and Behaviour in Children and Adults: A Systematic Review and Meta-Analysis. *International journal of environmental research and public health*, *18*(21), 11286. https://doi.org/10.3390/ijerph182111286

Sarkar, S., Khanna, P., & Singh, A. K. (2021). Impact of COVID-19 in patients with concurrent co-infections: A systematic review and meta-analyses. *Journal of medical virology*, *93*(4), 2385–2395. https://doi.org/10.1002/jmv.26740

Schiffrin, E. L., Flack, J. M., Ito, S., Muntner, P., & Webb, R. C. (2020). Hypertension and COVID-19. *American journal of hypertension*, *33*(5), 373–374. https://doi.org/10.1093/ajh/hpaa057

Seaton, R. A., Gibbons, C. L., Cooper, L., Malcolm, W., McKinney, R., Dundas, S., Griffith, D., Jeffreys, D., Hamilton, K., Choo-Kang, B., Brittain, S., Guthrie, D., & Sneddon, J. (2020). Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. *The Journal of infection*, *81*(6), 952–960. https://doi.org/10.1016/j.jinf.2020.09.024

Shahid, Z., Kalayanamitra, R., McClafferty, B., Kepko, D., Ramgobin, D., Patel, R., Aggarwal, C. S., Vunnam, R., Sahu, N., Bhatt, D., Jones, K., Golamari, R., & Jain, R. (2020). COVID-19 and Older Adults: What We Know. *Journal of the American Geriatrics Society*, *68*(5), 926–929. https://doi.org/10.1111/jgs.16472

Sjöström, A., Rysz, S., Sjöström, H., & Höybye, C. (2021). Electrolyte and acid-base imbalance in severe COVID-19. *Endocrine connections*, *10*(7), 805–814. https://doi.org/10.1530/EC-21-0265

Suleyman, G., Fadel, R. A., Malette, K. M., Hammond, C., Abdulla, H., Entz, A., Demertzis, Z., Hanna, Z., Failla, A., Dagher, C., Chaudhry, Z., Vahia, A., Abreu Lanfranco, O., Ramesh, M., Zervos, M. J., Alangaden, G., Miller, J., & Brar, I. (2020). Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. *JAMA network open*, *3*(6), e2012270. https://doi.org/10.1001/jamanetworkopen.2020.12270

Sultana, J., Cutroneo, P. M., Crisafulli, S., Puglisi, G., Caramori, G., & Trifirò, G. (2020). Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. *Drug safety*, *43*(8), 691–698. https://doi.org/10.1007/s40264-020-00976-7

Surjani, L., & Siahaan, J. M. (2020). Tinjauan Biomolekuler dan Klinis Ocular Covid-19. *Majalah Ilmiah Methoda, 10*(2), 53-66. doi:http://ojs.lppmmethodistmedan.net/

Tadolini, M., García-García, J. M., Blanc, F. X., Borisov, S., Goletti, D., Motta, I., Codecasa, L. R., Tiberi, S., Sotgiu, G., Migliori, G. B., & GTN TB/COVID group (2020). On tuberculosis and COVID-19 co-infection. *The European respiratory journal*, *56*(2), 2002328. https://doi.org/10.1183/13993003.02328-2020

Takagi, H., Kuno, T., Yokoyama, Y., Ueyama, H., Matsushiro, T., Hari, Y., & Ando, T. (2021). Meta-regression of COVID-19 prevalence/fatality on

socioeconomic characteristics of data from top 50 U.S. large cities. *Journal of medical virology*, *93*(2), 595–598. https://doi.org/10.1002/jmv.26335

Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T., Oh, J. E., Tokuyama, M., Lu, P., Venkataraman, A., Park, A., Liu, F., Meir, A., Sun, J., Wang, E. Y., Casanovas-Massana, A., Wyllie, A. L., Vogels, C., … Iwasaki, A. (2020). Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature*, *588*(7837), 315–320. https://doi.org/10.1038/s41586-020-2700-3

Tan, C., Huang, Y., Shi, F., Tan, K., Ma, Q., Chen, Y., Jiang, X., & Li, X. (2020). C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. *Journal of medical virology*, *92*(7), 856–862. https://doi.org/10.1002/jmv.25871

Tan, Y. K., Goh, C., Leow, A., Tambyah, P. A., Ang, A., Yap, E. S., Tu, T. M., Sharma, V. K., Yeo, L., Chan, B., & Tan, B. (2020). COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. *Journal of thrombosis and thrombolysis*, *50*(3), 587–595. https://doi.org/10.1007/s11239-020-02228-y

Taneri, P. E., Gómez-Ochoa, S. A., Llanaj, E., Raguindin, P. F., Rojas, L. Z., Roa-Díaz, Z. M., Salvador, D., Jr, Groothof, D., Minder, B., Kopp-Heim, D., Hautz, W. E., Eisenga, M. F., Franco, O. H., Glisic, M., & Muka, T. (2020). Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. *European journal of epidemiology*, *35*(8), 763–773. https://doi.org/10.1007/s10654-020-00678-5

Tao, Z., Xu, J., Chen, W., Yang, Z., Xu, X., Liu, L., Chen, R., Xie, J., Liu, M., Wu, J., Wang, H., & Liu, J. (2021). Anemia is associated with severe illness in COVID-19: A retrospective cohort study. *Journal of medical virology*, *93*(3), 1478–1488. https://doi.org/10.1002/jmv.26444

Tarlovskaya, E. I., Arutyunov, A. G., Konradi, A. O., Lopatin, Y. M., Rebrov, A. P., Tereshchenko, S. N., Chesnikova, A. I., Hayrapetyan, H. G., Babin, A. P., Bakulin, I. G., Bakulina, N. V., Balykova, L. A., Blagonravova, A. S.,

Boldina, M. V., Vaisberg, A. R., Galyavich, A. S., Gomonova, V. V., Grigorieva, N. Y., Gubareva, I. V., Demko, I. V., … Arutyunov, G. P. (2021). Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»). *Kardiologiia*, *61*(9), 20–32. https://doi.org/10.18087/cardio.2021.9.n1680

Thomson, R. J., Hunter, J., Dutton, J., Schneider, J., Khosravi, M., Casement, A., Dhadwal, K., & Martin, D. (2020). Clinical characteristics and outcomes of critically ill patients with COVID-19 admitted to an intensive care unit in London: A prospective observational cohort study. *PloS one*, *15*(12), e0243710. https://doi.org/10.1371/journal.pone.0243710

Violetis, O. A., Chasouraki, A. M., Giannou, A. M., & Baraboutis, I. G. (2020). COVID-19 Infection and Haematological Involvement: a Review of Epidemiology, Pathophysiology and Prognosis of Full Blood Count Findings. *SN comprehensive clinical medicine*, 1–5. Advance online publication. https://doi.org/10.1007/s42399-020-00380-3

Wang L. (2020). C-reactive protein levels in the early stage of COVID-19. *Medecine et maladies infectieuses*, *50*(4), 332–334. https://doi.org/10.1016/j.medmal.2020.03.007

Wei, W., Hu, X. W., Cheng, Q., Zhao, Y. M., & Ge, Y. Q. (2020). Identification of common and severe COVID-19: the value of CT texture analysis and correlation with clinical characteristics. *European radiology*, *30*(12), 6788–6796. https://doi.org/10.1007/s00330-020-07012-3

WHO. (2020). Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. https://www.who.int/publications-detail/clinicalmanagement-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected.

Writing Committee for the COMEBAC Study Group, Morin, L., Savale, L., Pham, T., Colle, R., Figueiredo, S., Harrois, A., Gasnier, M., Lecoq, A. L., Meyrignac, O., Noel, N., Baudry, E., Bellin, M. F., Beurnier, A., Choucha, W., Corruble, E., Dortet, L., Hardy-Leger, I., Radiguer, F., Sportouch, S., … Monnet, X. (2021). Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. *JAMA*, *325*(15), 1525–1534. https://doi.org/10.1001/jama.2021.3331

Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., Zhang, Y., Song, J., Wang, S., Chao, Y., Yang, Z., Xu, J., Zhou, X., Chen, D., Xiong, W., Xu, L., … Song, Y. (2020). Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA internal medicine*, *180*(7), 934–943. https://doi.org/10.1001/jamainternmed.2020.0994

Wu, Y., Xu, X., Chen, Z., Duan, J., Hashimoto, K., Yang, L., Liu, C., & Yang, C. (2020). Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain, behavior, and immunity*, *87*, 18–22. https://doi.org/10.1016/j.bbi.2020.03.031

Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., Tai, Y., Bai, C., Gao, T., Song, J., Xia, P., Dong, J., Zhao, J., & Wang, F. S. (2020b). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet. Respiratory medicine*, *8*(4), 420–422. https://doi.org/10.1016/S2213-2600(20)30076-X

Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., Wang, Y., Pan, S., Zou, X., Yuan, S., & Shang, Y. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet. Respiratory medicine*, *8*(5), 475–481. https://doi.org/10.1016/S2213-2600(20)30079-5

Yang, X., Yang, Q., Wang, Y., Wu, Y., Xu, J., Yu, Y., & Shang, Y. (2020). Thrombocytopenia and its association with mortality in patients with COVID-19. *Journal of thrombosis and haemostasis : JTH*, *18*(6), 1469–1472. https://doi.org/10.1111/jth.14848

Yin, T., Li, Y., Ying, Y., & Luo, Z. (2021). Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors. *BMC infectious diseases*, *21*(1), 200. https://doi.org/10.1186/s12879-021-05915-0

Zhang, Y., He, L., Chen, H., Lu, S., Xiong, Y., Liu, J., Zheng, Y., Wang, S., & Liu, L. (2020). Manifestations of blood coagulation and its relation to clinical outcomes in severe COVID-19 patients: Retrospective analysis. *International journal of laboratory hematology*, *42*(6), 766–772. https://doi.org/10.1111/ijlh.13273

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)*, *395*(10229), 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3

## LAMPIRAN

## LAMPIRAN 1 : BIODATA PENULIS

A. Data Pribadi

| | |
|---|---|
| Nama | : Emasari Kallang |
| Nama Panggilan | : Ema |
| Tempat, Tanggal Lahir | : Palopo, 03 September 1999 |
| Jenis Kelamin | : Perempuan |
| Agama | : Kristen Protestan |
| Alamat | : Bontoramba Lr. XII |
| Nama Ayah | : Alm. Anthonius Kallang |
| Nama Ibu | : Helena |
| Pekerjaan Orang Tua | : Ayah : Pensiunan PNS<br>Ibu : Pensiunan PNS |
| Alamat orang Tua | : Walenrang |
| Anak Ke | : 5 dari 5 bersaudara |
| No. Hp | : 082293069312 |
| Email | : Emasarikallang03@gmail.com |
| Hobby | : Menonton |
| Motto | : Work Hard Play Hard |

B. Pendidikan Formal

| Tahun | Institusi | Keterangan |
|---|---|---|
| 2004 – 2005 | TK | TK Silo Harapan Bangsa |
| 2005 - 2011 | SD | SDN 256 Pabuntang |
| 2011 – 2014 | SMP | SMPN 2 Lamasi |
| 2014 - 2017 | SMA | SMAN 21 Makassar |
| 2018 – Sekarang | UNIVERSITAS | Universitas Hasanuddin |

C. Riwayat Organisasi (5 Tahun Terakhir )

| Nama Organisasi | Jabatan | Tahun |
|---|---|---|
| PMK FK-FKG Unhas | Anggota | 2018 - Sekarang |
| BEM FK Unhas | Anggota | 2020 - 2021 |

**LAMPIRAN 2 :**

**Tabel Data Hasil Covid-19 Di Rumah Sakit Universitas Hasanuddin Di Ruangan ICU.**

| NO | NO.RM | NAMA | JENIS KELAMI | UMUR | KOMORBID | ASAL PAPARAN | LAMA PERAWATAN | PRM. RADIOLOGI | HB | HCT | PCT | MCH | MCV | PLT | LEUKOSIT | MCHC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 163262 | B | L | 60tahun | hipoalbumin, pneumonia, peningkatan enzim hati | | 13 hari | PNEUMONIA | 16 | 45,6 | 0,06 | 29,5 | 84 | 400 | 8,71 | 35,2 |
| 2 | 163890 | I A B | L | 58tahun | ards, peningkatan enzim hati | RIW.MAMUJU ADA, RIW.KONTAK TDK DIKETAHUI. | 3hari | PNEUMONIA BILateral typical covid-19 , cardiomegaly disertai dilatatio aortae | 13 | 37 | 0,28 | 29,8 | 84,9 | 260 | 8,6 | 35,1 |
| 3 | 136460 | A R M | L | 76tahun | hipertensi,dm,gik,ards, koagulopati | tdk ada riw kontak dgn pasien covid | 15hari | pnemonia dextra,cardiomegaly disertai dilatatio, elongatio et atherosclerosis aortae | 14,8 | 42 | 0,17 | 30,1 | 85,4 | 175 | 22,46 | 35,2 |
| 4 | 162484 | H S T | L | 47TAHUN | peningkatan enzim hati, koagulopati, | tdk ada riw kontak, | 10hari | bronchopneumonia dengan proses spesifik aktif | 15,2 | 46,2 | 86 | 28,7 | 87,3 | 193 | 14,99 | 32,9 |
| 5 | 162161 | H.M.I M | L | 68tahun | gangguan elektrolit, HT, koagulopati,hipoalbumin, epilepsi, inf | tdk ada riw kontak, | 12hari | pneumonia bilateral, cardiomegaly disertai dilatatio et atherosclerosis aortae | 12,4 | 32,6 | 0,18 | 30 | 78,9 | 185 | 7,64 | 38 |
| 6 | 121524 | P B S | L | 84tahun | Acute confusional state, sepsis, stress ulcer,hipernatremi, ak | dtng dgn keadra menurun, sesak napas 2hari lalu, | 3hari | pnemonia bilateral, cardiomegaly disertai tanda" edema paru, dilatatio elongatio et atherosclerosis aortae | 7,6 | 26,2 | 0,27 | 27 | 93,2 | 254 | 14,84 | 29 |
| 7 | 161927 | H J | L | 81tahun | hipertensi, HHD, ARDS, stroke Hr, hipoalbumin, trombositope | - | 2hari | cardiomegaly dengan edema paru, dilatatio et atherosclerosis aortae | 14,4 | 42,7 | 0,13 | 32,6 | 96,6 | 115 | 22,86 | 33,7 |
| 8 | 36268 | M M | L | 79tahun | dm,hipertensi,jantung koroner, | - | 6hari | pnemonia bilateral, cardiomegaly disertai dilatatio, elevasi diafragma dextra | 17,5 | 52,6 | 0,17 | 30,5 | 91,8 | 157 | 4,66 | 33,3 |
| 9 | 162503 | M J M | L | 64tahun | koagulopati, | demam 7hari lalu,batuk. | 8hari | - | 15 | 44,5 | - | 32,5 | 96,5 | 232 | 12,67 | 33,7 |
| 10 | 161732 | H. M. D | L | 56 TAHUN | hipertensi, ards, ckd,dm, anemia, koagulopati | - | 3hari | pneumonia bilateral, cardiomegaly disertai dilatatio et atherosclerosis aortae | 10,8 | 32,1 | 0,24 | 28,2 | 84,8 | 241 | 7,77 | 33,6 |
| 11 | 161027 | H H H | L | 85 TAHUN | hipertensi , hipoalbumin, ards, | kontk dgn pasien covid (anak) | 13hari | pnemonia bilateral, suspek efusi pleura, cardiomegaly | 13 | 37 | 0,13 | 31,6 | 90 | 138 | 5,04 | 35,1 |
| 12 | 9198 | M S | L | 66 tahun | dm,hipertensi , koagulopati, ensefalopati, sepsis | kontk dgn pasien covid | 6hari | pneumonia bilateral , dilatatio et atherosclerosis aortae | 14,1 | 40,8 | 0,12 | 29,6 | 85,5 | 115 | 3,74 | 34,6 |
| 13 | 7936 | M T | L | 70tahun | hipertensi, ards | - | 12hari | pneumonia bilateral, fibrosis pulmo dextra, cardiomegaly disertai dilatatio, elongatio et atherosclerosis aortae | 13,2 | 37,8 | 0,19 | 30,6 | 87,7 | 195 | 5,83 | 34,9 |
| 14 | 161599 | T J | L | 47 TAHUN | dm ,pneumonia, ARDS, | - | 10hari | pneumonia bilateral | 14,6 | - | - | - | - | 131 | 6100 | - |
| 15 | 163219 | Hi. A. N, B | P | 72 TAHUN | hipertensi,covid,peningkatan enzim hati, Aki,Hipoalbumin | - | 13hari | PNEUMONIA BILateral typical covid-19 , cardiomegaly disertai dilatatio aortae | 12,4 | 37,5 | 0,22 | 27,8 | 84,1 | 209 | 7,65 | 33,1 |
| 16 | 162943 | H. A M | L | 68tahun | DM, ards, ht | - | 6hari | pnemonia bilateral | 13 | 37 | 0,27 | 29,4 | 83,7 | 281 | 4,94 | 35,1 |
| 17 | 163646 | O | L | 40tahun | ards, | tdk ada riw kontak dgn pasien covid | 6hari | pnemonia bilateral, atherosclerosis aortae | 12,7 | 36 | 0,15 | 29,3 | 83,1 | 155 | 4,72 | 35,3 |
| 18 | 163985 | S | P | 84tahun | hipertensi, ensefalopati, stroke non HR, | tdk ada riw kontak dgn pasien covid | 4hari | pnemonia bilateral, dilatatio et elongatio aortae | 14,3 | 41,9 | 0,19 | 28,8 | 84,5 | 192 | 6,07 | 34,1 |
| 19 | 140011 | A D T | L | 71tahun | dm, ards | tdk ada riw kontak dgn pasien covid | 1hari | pnemonia bilateral | 13,3 | 37 | 0,17 | 25,6 | 85,9 | 181 | 4,75 | 30,5 |
| 20 | 165868 | Hi. A S B | P | 57 TAHUN | CH,Hid,cbc,hipertensi | kontk dgn pasien covid (suami) | 12hari | pneumonia pulmo bilateral, cardiomegaly | 13 | 39,5 | 0,38 | 27,8 | 84,6 | 371 | 10,32 | 32,9 |
| 21 | 76798 | B dg, R | L | 67tahun | pad | tdk ada riw kontak dgn pasien covid | 3hari | - | 12,5 | 38,5 | tdk ada | 30,3 | 93,2 | 119 | 24,55 | 32,5 |
| 22 | 23995 | T I | L | 64tahun | hipertensi, jantung koroner, | tdk ada riw kontak dgn pasien covid | 8hari | pnemonia bilateral, cardiomegaly disertai dilatatio et atherosclerosis aortae | 13,5 | 41,8 | 0,26 | 32,1 | 99,3 | 271 | 14,66 | 32,3 |
| 23 | 166996 | H | P | 47tahun | hipertensi, dm, edem paru akut,ateral fibrilasi, chf | tdk ada riw kontak dgn pasien covid | 10hari | pnemonia dextra, lymphadenopathy hillar dextra, cardiomegaly | 14,4 | 43,9 | 0,27 | 26,4 | 80,4 | 260 | 9,03 | 32,8 |
| 24 | 165415 | M | P | 70tahun | hipertensi, kanker ovarium, ascites, efusi pleura, | tdk ada riw kontak dgn pasien covid | 19hari | efusi pleura bilateral, atherosclerosis aortae | 11,8 | 37,8 | 493 | 26,2 | 83,8 | 493 | 4,87 | 31,2 |
| 25 | 162109 | H. M N | L | 63tahun | hipertensi, ards, | tdk ada riw kontak dgn pasien covid | 3hari | pnemonia sinistra | 14,9 | 44,5 | 0,2 | 30,1 | 89,9 | 202 | 12,57 | 33,5 |
| 26 | 160774 | D I P | P | 51tahun | hipertensi, ards, dm, hipoalbumin | ada riwyat keluar kota (jakarta) | 10hari | pnemonia bilateral | 13,1 | 40,7 | 0,32 | 26,9 | 83,6 | 318 | 13,16 | 32,2 |
| 27 | 152344 | A F | L | 73tahun | hipertensi, hipoalbuminemia, koagulopati | tdk ada riw kontak dgn pasien covid | 13hari | pnemonia bilateral, dilatatio aortae | 12,1 | 38,3 | tdk ada | 22 | 38,3 | 134 | 4,17 | 31,6 |
| 28 | 10231 | M U | L | 73tahun | dm, hipertensi, hipoalbumin | ada kontak dgn pasien covid(ciri) | 4hari | pnemonia bilateral | 11,6 | 29,8 | 0,34 | 33,2 | 82,8 | 356 | 6,06 | 38,9 |
| 29 | 161707 | ABD. W M | L | 73tahun | ards, ppk, ht, hipoalbumin, | tdk ada riw kontak dgn pasien covid | 2hari | pnemonia bilateral, cardiomegali disertai dilatatio et atherosclerosis aortae | 15,1 | 43 | - | 29 | 86,5 | 225 | 8,4 | 35,1 |
| 30 | 162161 | H. D M | P | 78tahun | hipertensi, koagulopati | tdk ada riw kontak dgn pasien covid | 4hari | pnemonia bilateral typical viral infection, cardiomegaly disertai atherosclerosis aortae | 13,1 | 40,4 | 0,3 | 26,4 | 81,3 | 312 | 7,81 | 32,4 |
| 31 | 3624 | D S | L | 67tahun | ards, pneumonia, ckd, ahipertensi, DM, anemia, hipoalbumin | tdk ada riw kontak dgn pasien covid | 13 hari | cardiomegaly disertai pneu, intastial,efusi pleura minimal | 9 | 27,8 | 0,43 | 28,6 | 88,3 | 490 | 18,45 | 32,4 |
| 32 | 162242 | H J P | P | 69tahun | dm,kolesterol,hipertensi | tdk ada riw kontak dgn pasien covid | 11hari | atelektasis pulmo sinistra, pnemonia disertai lymphadenopaty dextra | 12,3 | 36,3 | 0,21 | 27 | 79,6 | 199 | 8,81 | 33,9 |
| 33 | 163330 | I P | L | 66tahun | dm, hipertensi, hipoalbumin, gangguan elektrolit | tdk ada riw kontak dgn pasien covid | 6hari | pnemonia bilateral , slight cardiomegaly disertai dilatatio aortae | 12,9 | 36,9 | 0,31 | 29,9 | 85,4 | 333 | 6,64 | 35 |
| 34 | 163212 | I A R | P | 72tahun | dm, hipertensi | tdk ada riw kontak dgn pasien covid | 5hari | pnemonia bilateral, cardiomegaly disertai tanda" edema paru, elevasi diafragma dextra | 12,6 | 37 | 0,23 | 28,8 | 84,5 | 230 | 11,41 | 34,1 |
| 35 | 164087 | N H | P | 18 TAHUN | ensefalopathy sepsi. anemia et causa suspek penyakit kronik, | tdk ada riw kontak dgn pasien covid | 9hari | pnemonia bilateral, cor normal | 8,4 | 26,8 | 0,55 | 27,5 | 87,6 | 661 | 20,91 | 31,3 |
| 36 | 162250 | A M A S | L | 59tahun | dm | tdk ada riw kontak dgn pasien covid | 3hari | pnemonia bilateral | 14,9 | 41,7 | 0,11 | 31 | 86,7 | 97 | 4,14 | 35,7 |
| 37 | 24283 | DRS. A | L | 66 tahun | hipertensi, anemia, | ada kontak dgn pasien covid | 8hari | pnemonia bilateral susp, viral infection, cardiomegaly | 9,7 | 31,5 | 0,2 | 21,9 | 71,3 | 206 | 4,1 | 30,8 |
| 38 | 135573 | M Y | L | 46tahun | hipertensi, chronic kidney diseases on cirrhosis, dm, anemia | tdk ada riw kontak dgn pasien covid | 10hari | slight cardiomegaly disertai elongatio aortae, pulmo normal | 8,4 | 24,5 | 0,2 | 28,6 | 83,3 | 205 | 3,02 | 34,3 |
| 39 | 18209 | S | L | 83tahun | hipertensi | tdk ada riw kontak dgn pasien covid | 2hari | tdk dilakukan foto thorax krna mngitn desaturasi sejak masuk, evklasia tdk memungkinkan dilakukan | 13,1 | 39,6 | 0,12 | 29,4 | 88,8 | 109 | 7,37 | 33,1 |
| 40 | 91509 | A H | L | 62TAHUN | ards, | rwt kontak dgn pasien covid tdk diketahui | 10hari | pnemonia dextra,cardiomegaly disertai dilatatio, elongatio et atherosclerosis aortae | 13,8 | 40,9 | 0,17 | 27,1 | 80,4 | 164 | 11,41 | 33,7 |
| 41 | 161545 | H.A N M | P | 73tahun | hipertensi, dm, ards | rwt kontak dgn pasien covid tdk diketahui | 6hari | pnemonia bilateral, cardiomegaly | 15,4 | 46,7 | 0,16 | 26,7 | 80,9 | 150 | 10,36 | 33 |
| 42 | 150510 | Y A | P | 63tahun | koagulopati, | tdk ada riw kontak dgn pasien covid | 11hari | pnemonia bilateral, efusi pleura bilateral | 15,5 | 46,9 | 0,17 | 30,1 | 91,1 | 166 | 5,9 | 33 |
| 43 | 29727 | H H S | P | 70tahun | ards, koagulopati | tdk ada riw kontak dgn pasien covid | 10hari | pnemonia bilateral, cardiomegaly disertai atherosclerosis aortae | 12,5 | 39,7 | 0,18 | 26,5 | 84,1 | 156 | 14,68 | 31,5 |
| 44 | 161807 | L S | P | 65tahun | hipertensi, ards, | rwt kontak dgn pasien covid tdk diketahui | 7hari | pnemonia bilateral luas, cardiomegaly disertai dilatatio aorta, suspek efusi pleura sinistra | 12,2 | 37,6 | 0,18 | 31,9 | 98,4 | 175 | 10,46 | 32,4 |
| 45 | 162829 | M A | L | 48tahun | dm, | tdk ada riw kontak dgn pasien covid | 4hari | - | 15,8 | 46,9 | 0,29 | 28,5 | 84,7 | 251 | 18,99 | 33,7 |
| 46 | 162822 | H. A T | L | 78tahun | hipertensi, koagulopati | rwt kontak dgn pasien covid tdk diketahui | 7hari | pnemonia bilateral | 11,9 | 36,8 | 0,25 | 28,1 | 87 | 244 | 4,62 | 32,3 |
| 47 | 162365 | D U E B | P | 57tahun | TDK ADA komorbid dan privat penyerta | rwt kontak dgn pasien covid tdk diketahui | 9hari | pnemonia bilateral | 10,5 | 32,5 | 0,12 | 30,6 | 94,8 | 107 | 4,62 | 32,3 |
| 48 | 147128 | H | L | 62TAHUN | hipertensi, | tdk ada riw kontak dgn pasien covid | 2hari | pnemonia bilateral | 13,5 | 38,9 | 0,22 | 28,2 | 81,2 | 258 | 8,5 | 34,7 |
| 49 | 162588 | I | P | 57tahun | post TB, koagulopati | rwt kontak dgn pasien covid tdk diketahui | 4hari | pnemonia bilateral | 12,6 | 37,2 | 0,11 | 28,1 | 82,9 | 106 | 3,96 | 33,9 |
| 50 | 15876 | H | L | 30tahun | ards, koagulopati, peningkatan enzim hati, | rwt kontak dgn pasien covid tdk diketahui | 10hari | pnemonia bilateral | 14,9 | 43,2 | 0,22 | 28,9 | 83,9 | 258 | 5,66 | 34,5 |
| 51 | 56761 | M | P | 58tahun | hipertensi, dm. ali/did | tdk ada riw kontak dgn pasien covid | 6hari | pnemonia bilateral, cardiomegaly disertai dilatatio aortae | 8,7 | 26,5 | 0,25 | 32,2 | 98,1 | 267 | 7,55 | 32,8 |
| 52 | 44843 | M I | L | 59tahun | hipertensi, dm, pasien on hd 3x seminggu, ards, adhf, ckd, an | tdk ada riw kontak dgn pasien covid | 4hari | cardiomegaly disertai tanda" edema paru,atherosclerosis aortae, efusi pleura bilateral | 8,9 | 28,2 | 0,24 | 28,3 | 89,8 | 268 | 6,52 | 31,6 |
| 53 | 163068 | R | P | 65tahun | ards, koagulopati, | rwt kontak dgn pasien covid tdk diketahui | 10hari | pnemonia bilateral | 11,4 | 35,1 | 0,38 | 28,6 | 88,2 | 340 | 16,14 | 32,5 |

| RBC | IL 6 | PT | APTT | ALBUMIN | D-DIMER | CRP | RIW. VAKSIN | RIWAYAT | antibiotik | antivirus |
|---|---|---|---|---|---|---|---|---|---|---|
| 5,43 | 18,4 | 14,5 inr 1,2 | 29,6 | 2,9 | 1,66 | positif 16 | tdk ada | ✓ | meropenem | remdesivir |
| 4,36 | 427 | - | - | 3 | 58,1 | - | - | mnggl | meropenem, moxifloxacin, | remdesivir |
| 4,92 | 17,5 | - | - | 2,9 | 1260 | negatif | - | mnggl | moxifloxacin, azithromycin, | remdesivir |
| 5,29 | - | 12,2 | 22,6 | 3,6 | 870 | - | - | ✓ | levofloxacin, azithromycin | remdesivir |
| 4,13 | 19,6 | 15,2 inr 1,2 | 37,1 | 2,7 | 4230 | - | - | ✓ | Levofloxacin, azithromycin, meropene | remdesivir |
| 2,81 | - | - | - | - | - | - | - | mnggl | - | remdesivir |
| 4,42 | 19,6 | - | - | 2,3 | - | - | - | mnggl | Levofloxacin, | remdesivir |
| 5,73 | - | - | - | - | 6,52 | - | - | mnggl | azithromyciin | favipiravir,remdesivir, |
| 4,61 | - | - | - | 2,7 | 2840 | - | - | ✓ | meropenem, levofloxacin, | remdesivir |
| 3,83 | - | 13 inr 1,11 | 43,9 | - | - | - | - | ✓ | meropenem,moxifloxacin,azithromyci | remdesivir |
| 4,11 | 7,42 | - | - | 3,2 | 597 | positif 12 | - | ✓ | Levofloxacin, azithromycin, meropene | remdesivir, favipiravir |
| 4,77 | 16 | - | - | 2,6 | 1120 | - | - | mnggl | Levofloxacin, azithromycin, meropene | remdesivir, |
| 4,31 | 2,66 | - | - | 3 | 1,46 | kuantitatif 171,1 | - | ✓ | Levofloxacin, | favipiravir,remdesivir, |
| - | - | - | - | - | 87 | - | tdk ada | mnggl | moxifloxacin, azithromycin, meropene | remdesivir |
| 4,46 | 8,26 | 15 inr 1,28 | 35,4 | 2,9 | 0,59 | positif 32 | tdk ada | mnggl | meropenem, levofloxacin, | remdesivir |
| 4,42 | 131 | - | - | 3,1 | 1,41 | - | - | ✓ | Levofloxacin, azithromycin, | remdesivir |
| 4,33 | - | 12,1 inr 0,9 | 29,6 | - | - | - | - | mnggl | azithromyciin | favipiravir, |
| 4,96 | - | - | - | 2,7 | 1,19 | semikuantitatif 48 | - | mnggl | Levofloxacin, azithromycin, | remdesivir |
| 4,41 | 83,4 | - | - | 3,4 | 435 | 142,5 | - | ✓ | azithromycin | remdesivir |
| 4,67 | - | 15,5 inr 1,3 | 24,5 | 3,1 | 1320 | semikuantitatif 24 | - | ✓ | meropenem | remdesivir |
| 4,13 | - | - | - | - | - | - | - | mnggl | Levofloxacin, azithromycin, | remdesivir |
| 4,21 | - | - | - | 3,4 | 242 | - | - | ✓ | Levofloxacin, azithromycin, | remdesivir |
| 5,46 | - | 17,2 inr 1,4 | 29 | 4,2 | 631 | negatif | tdk ada | ✓ | - | remdesivir |
| - | - | - | - | 3,2 | 3500 | - | - | mnggl | - | remdesivir |
| 4,95 | - | - | - | - | 6,24 | - | - | ✓ | meropenem, levofloxacin, | remdesivir |
| 4,87 | 22,3 | 13,2 inr 1,0 | 22,3 | 2,8 | 362 | negatif | - | ✓ | meropenem, levofloxacin, | remdesivir |
| 5,5 | - | 13,8 inr 1,1 | 33,1 | 2,8 | >5000 | - | - | mnggl | Levofloxacin, | remdesivir |
| 3,6 | - | - | - | 2,8 | 2240 | - | ada (1) | mnggl | Levofloxacin, azithromycin, | remdesivir |
| - | - | - | - | 3,3 | 1,05 | positif 1/8(48mg/ | - | dirujuk krna t | Levofloxacin, | remdesivir |
| 4,97 | - | - | - | - | 8 | - | - | ✓ | moxifloxacin | remdesivir |
| 3,15 | - | 15 inr1,25 | 26,8 | 2,1 | 3380 | - | tdk ada | ✓ | kotrimoksazol | remdesivir |
| 4,56 | | | | 2,7 | 738 | | | mnggl | moxifloxacin, azithromycin, | remdesivir, |
| 4,32 | - | - | - | 2,4 | 4,99 | positif 1/16(128) | - | mnggl | levofloxacin, meropenem, azithromyc | remdesivir |
| 4,38 | 788 | 15 inr 1,34 | 46,1 | - | 11214,52 | - | - | mnggl | levofloxacin, azithromycin | remdesivir |
| 3,06 | - | - | - | 2,2 | 11,5 | - | - | mnggl | ceftriaxone, metrodinazol, | remdesivir |
| 4,81 | - | - | - | - | - | - | - | mnggl | - | - |
| 4,42 | - | - | - | 2,6 | 3,9 | - | - | MNGGL | azithromycin, levofloxacin, | remdesivir |
| 2,94 | - | - | - | - | - | - | - | mnggl | azithromycin , ceftriaxone | oseltamivir, remdesivir |
| 4,46 | - | - | - | - | 4110 | - | - | mnggl | moxifloxacin, | remdesivir |
| 5,09 | - | 15,7 inr 1,3 | 28,8 | 2 | 3,74 | - | - | mnggl | levofloxacin | remdesivir |
| 5,77 | - | - | - | 2,5 | - | - | - | mnggl | meropenem, levofloxacin, | remdesivir |
| 5,15 | 27,6 | 10,5 inr 1,7 | 39 | 3,3 | 345 | negatif | - | ✓ | - | remdesivir |
| 4,72 | - | 14,9 inr 1,2 | 35,2 | 2,4 | 912 | - | - | mnggl | levofloxacin | remdesivir |
| 3,82 | - | - | - | - | 1,36 | - | - | mnggl | meropenem, levofloxacin, | remdesivir |
| 5,54 | - | - | - | - | - | - | - | mnggl | Levofloxacin | remdesivir |
| 4,23 | - | 13,1 inr 1,0 | 39,5 | 2,9 | 993 | positif | vaksin lengkap | mnggl | levofloxacin | remdesivir |
| 3,43 | - | - | - | 3,1 | 920 | - | - | ✓ | Levofloxacin | remdesivir |
| 4,79 | - | - | - | - | - | - | - | mnggl | azithromycin, moxifloxacin, meropen | remdesivir |
| 4,49 | - | 13 inr 1,04 | 35,3 | - | 1220 | - | tdk ada | mnggl | - | remdesivir |
| 5,15 | - | - | - | 3,6 | 1,17 | - | - | mnggl | Levofloxacin, meropenem, | remdesivir |
| 2,7 | 103 | - | - | 2,1 | 1760 | - | - | ✓ | azithromycin, levofloxacin, | remdesivir |
| 3,14 | - | 20,1 inr 1,8 | 33,1 | 2,1 | 2870 | - | - | mnggl | - | remdesivir |
| 3,98 | 2,04 | 19,4 inr 1,7 | 28,2 | 2,3 | 9,7 | - | tdk ada | ✓ | Levofloxacin, azithromycin | remdesivir |

**LAMPIRAN 3 :**

**Surat Permohonan Izin Penelitian**

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,
RISET, DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
**PROGRAM STUDI SARJANA KEDOKTERAN**
Jl. Perintis Kemerdekaan Km. 10 Tamalanrea, Makassar 90245, Telp. (0411) 587436, Fax. (0411) 586297

Nomor : 20520/UN4.6.8/PT.01.04/2021
Lamp : ---
Hal : Permohonan Izin Penelitian

27 September 2021

Kepada Yth. :
Direktur RSP Universitas Hasanuddin
Di-
Makassar

Dengan hormat, disampaikan bahwa mahasiswa Program Studi Pendidikan Dokter Fakultas Kedokteran Universitas Hasanuddin di bawah ini :

N a m a : Emasari Kallang
N i m : C011181366

bermaksud melakukan penelitian di RSP Universitas Hasanuddin dengan judul penelitian **"Gambaran Kasus Covid-19 Dengan Perawatan ICU Di Rumah Sakit Universitas Hasanuddin Periode Januari-Desember 2020"**

Sehubungan hal tersebut kiranya yang bersangkutan dapat diberi izin untuk melakukan Penelitian dalam rangka penyelesaian studinya.

Demikian permohonan kami, atas bantuan dan kerjasamanya disampaikan terima kasih.

Ketua,
Program Studi Sarjana Kedokteran
Fakultas Kedokteran Unhas

Dr. dr. Sitti Rafiah,MSi
NIP. 196805301997032001

*Tembusan Yth :*
*1. Arsip*

**LAMPIRAN 4 :**

**Rekomendasi Persetujuan Etik**

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

**REKOMENDASI PERSETUJUAN ETIK**
Nomor : 633/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 29 September 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

| | | | |
|---|---|---|---|
| No Protokol | UH21090605 | No Sponsor Protokol | |
| Peneliti Utama | **Emasari Kallang** | Sponsor | |
| Judul Peneliti | Gambaran kasus Covid-19 dengan perawatan ICU di rumah sakit Universitas Hasanuddin periode Januari-Desember 2020 | | |
| No Versi Protokol | **1** | Tanggal Versi | **1 Oktober 2021** |
| No Versi PSP | | Tanggal Versi | |
| Tempat Penelitian | RS Universitas Hasanuddin Makassar | | |
| Jenis Review | [x] Exempted<br>[ ] Expedited<br>[ ] Fullboard Tanggal | Masa Berlaku **29 September 2021** sampai **29 September 2022** | Frekuensi review lanjutan |
| Ketua Komisi Etik Penelitian Kesehatan FKUH | Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)** | Tanda tangan | |
| Sekretaris Komisi Etik Penelitian Kesehatan FKUH | Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)** | Tanda tangan | |

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

**LAMPIRAN 5 :**

**Surat Keterangan Selesai Penelitian**

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,
RISET, DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
**RUMAH SAKIT UNHAS**

Jl. Perintis Kemerdekaan Km. 10 Tamalanrea, Makassar 90245

*Website.www.rs.unhas.ac.id.Email.info@rs.unhas.ac.id* Telp: (0411) 591331 Fax: (0411) 591332

Nomor : 4402/UN4.24.1.2/PT.01.05/2022 24 Mei 2022
Hal : Surat Keterangan Selesai Penelitian

Dengan ini menerangkan bahwa mahasiswa yang beridentitas :

| | |
|---|---|
| Nama | : Emasari Kallang |
| NIM | : C011181366 |
| Institusi | : Universitas Hasanuddin Makassar |
| Kode Penelitian | : 211012_1 |

Telah menyelesaikan penelitian di Rumah Sakit Unhas.

| | |
|---|---|
| Terhitung pada tanggal | : 30 Desember 2021 |
| Dengan Sampel | : Data Sekunder: Data RM Pasien Covid-19 dengan perawatan ICU |

Dalam rangka penyusunan Skripsi yang berjudul:

**"GAMBARAN KASUS COVID-19 DENGAN PERAWATAN ICU DI RUMAH SAKIT UNIVERSITAS HASANUDDIN PERIODE JANUARI-DESEMBER 2020"**

Demikian surat keterangan ini dibuat dan diberikan kepada yang bersangkutan untuk dipergunakan seperlunya.

**Kepala Bidang Penelitian dan Inovasi**

**dr. Aslim Taslim,Sp.Onk.Rad, M.Kes**
**NIP. 198304252012121003**